Recombinant Human Interferon- -1a (Rebif) vs Recombinant Interferon- -1b (Betaseron) in Healthy Volunteers: A Pharmacodynamic and Tolerability Study

Author： Buraglio M.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.18, Iss.1, 1999-07, pp. : 27-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Subcutaneous Recombinant Interferon- -1a (Rebif®): A Review of its Use in Relapsing-Remitting Multiple Sclerosis

By Murdoch David   Lyseng-Williamson Katherine A.  

Drugs, Vol. 65, Iss. 9, 2005-01 ,pp. : 1295-1312

Adis International

Access to resources Recommend Favorite

Subcutaneous Recombinant Interferon-β-1a (Rebif®): A Review of its Use in the Treatment of Relapsing Multiple Sclerosis

By Sanford Mark   Lyseng-Williamson Katherine A.  

Drugs, Vol. 71, Iss. 14, 2011-10 ,pp. : 1865-1891

Adis International

Access to resources Recommend Favorite

Bioequivalence of Two Recombinant Interferon -2b Liquid Formulations in Healthy Male Volunteers

By Idrian Garcia-Garcia  

Drugs in R&D, Vol. 5, Iss. 5, 2004-01 ,pp. : 271-280

Adis International

Access to resources Recommend Favorite

Berlex, Inc. has issued a letter reminding prescribers of hepatotoxicity associated with Betaseron [interferon--1b].

By  

Reactions Weekly, Vol. 1, Iss. 1049, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Haematological Effects of Interferon-β-1a (Rebif ® ) Therapy in Multiple Sclerosis

By Rieckmann Peter  

Drug Safety, Vol. 27, Iss. 10, 2004-01 ,pp. : 745-756

Adis International

Access to resources Recommend Favorite